Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
9
SYRS Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
-15.9%
Day range:
$0.0002 - $0.0101
52-week range:
$0.0001 - $0.2969
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.02x
P/B ratio:
9.66x
Volume:
4.2K
Avg. volume:
35.7K
1-year change:
-99.89%
Market cap:
$5.4K
Revenue:
$9.9M
EPS (TTM):
-$3.07
Analysts' Opinion
-
Consensus RatingSyros Pharmaceuticals, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Syros Pharmaceuticals, Inc. has an estimated upside of 499900% from its current price of $0.0002.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.0002.
Fair Value
-
According to the consensus of 3 analysts, Syros Pharmaceuticals, Inc. has 499900% upside to fair value with a price target of -- per share.
SYRS vs. S&P 500
-
Over the past 5 trading days, Syros Pharmaceuticals, Inc. has underperformed the S&P 500 by -0.38% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Syros Pharmaceuticals, Inc. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Syros Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Syros Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Syros Pharmaceuticals, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Syros Pharmaceuticals, Inc. reported earnings per share of -$0.16.
Enterprise value:
2M
EV / Invested capital:
--
Price / LTM sales:
0.02x
EV / EBIT:
--
EV / Revenue:
5.07x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.02x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $23.4M | $8.8M | $386K | $3.8M | -- | |
| Gross Profit | $13.4M | $6.1M | -$883K | $3.1M | -$325K | |
| Operating Income | -$115.8M | -$135.5M | -$111.5M | -$32.3M | -$26.2M | |
| EBITDA | -$112.8M | -$132.7M | -$110.3M | -$31.7M | -$25.9M | |
| Diluted EPS | -$16.39 | -$3.76 | -$3.03 | -$1.43 | -$0.16 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $98.6M | $153.3M | $252.3M | $122.5M | $63.9M | |
| Total Assets | $133.3M | $208M | $284.7M | $147.8M | $85M | |
| Current Liabilities | $28.1M | $29.9M | $38.4M | $28.4M | $28.4M | |
| Total Liabilities | $87.4M | $102M | $155.6M | $111.5M | $96.1M | |
| Total Equity | $45.9M | $106.1M | $129.2M | $36.3M | -$11.1M | |
| Total Debt | $45.4M | $63.8M | $62M | $60.2M | $57.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$115M | -$122.3M | -$100M | -$31.9M | -$20.7M | |
| Cash From Investing | $29.2M | $73.5M | $1.9M | $28.6M | -- | |
| Cash From Financing | $141.8M | -$10.6M | $43.2M | $57K | -- | |
| Free Cash Flow | -$115.8M | -$123.2M | -$100.1M | -$31.9M | -$20.7M | |
SYRS
Sector
Market Cap
$5.4K
$25.2M
Price % of 52-Week High
0.07%
49.83%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.77%
1-Year Price Total Return
-99.89%
-21.9%
Beta (5-Year)
1.099
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0003
200-day SMA
Sell
Level
$0.0082
Bollinger Bands (100)
Sell
Level
0.0009 - 0.0009
Chaikin Money Flow
Sell
Level
-430.2K
20-day SMA
Sell
Level
$0.0005
Relative Strength Index (RSI14)
Sell
Level
45.5512
ADX Line
Buy
Level
13.7755
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$0.0005
MACD (12, 26)
Sell
Level
0.0000
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Sell
Level
-426.1K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-7.4982)
Sell
CA Score
(Annual)
Level (-4.6197)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (6.5441)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, SYRS has received 0 Buy ratings 3 Hold ratings, and 0 Sell ratings. The SYRS average analyst price target in the past 3 months is --.
-
Where Will Syros Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Syros Pharmaceuticals, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Syros Pharmaceuticals, Inc.?
Analysts are divided on their view about Syros Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Syros Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Syros Pharmaceuticals, Inc.'s Price Target?
The price target for Syros Pharmaceuticals, Inc. over the next 1-year time period is forecast to be -- according to 3 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is SYRS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Syros Pharmaceuticals, Inc. is a Hold. 3 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of SYRS?
You can purchase shares of Syros Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Syros Pharmaceuticals, Inc. shares.
-
What Is The Syros Pharmaceuticals, Inc. Share Price Today?
Syros Pharmaceuticals, Inc. was last trading at $0.0000 per share. This represents the most recent stock quote for Syros Pharmaceuticals, Inc.. Yesterday, Syros Pharmaceuticals, Inc. closed at $0.0002 per share.
-
How To Buy Syros Pharmaceuticals, Inc. Stock Online?
In order to purchase Syros Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SYRS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SYRS
Sector
P/E ratio
--
23.30x
PEG ratio
--
-0.01x
P/B ratio
9.66x
1.78x
Price / LTM sales
0.02x
1.55x
Growth Metrics
SYRS
Sector
Revenue growth
--
3.69%
Earnings growth
--
9.95%
Revenue (5-year growth)
37.12%
6.38%
Earnings forecast
-$0.76
-$0.19
Profitability
SYRS
Sector
Profitability FY 2025
--
$2.6M
Return on invested capital
--
-33.25%
Return on assets
--
-29.67%
Return on equity
--
-38.66%
Earnings Date
Last Earnings Date
Mar
31
Next Earnings Date
Feb
20
Estimated Next Earnings Date
May
22
Balance Sheet
SYRS
Sector
Total cash
$58.3M
$25.1M
Short term investments
--
$24M
Total assets
$168.2M
$72.5M
Long term debt
--
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
